logo

ONCY

Oncolytics Biotech
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
consensus rating "Strong Buy"
Bearish Engulfing
EPS Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About ONCY

Oncolytics Biotech Inc.

A Canadian company that develops oncolytic viruses for the treatment of cancers

Biological Technology
04/02/1998
06/01/2018
NASDAQ Stock Exchange
28
12-31
Common stock
804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5
--
Oncolytics Biotech Inc., was incorporated on April 2, 1998 under the laws of Alberta as an Alberta limited liability company. The company is a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the immune system's ability to fight cancer, making tumors more vulnerable to extensive tumor treatment.

Company Financials

EPS

ONCY has released its 2024 Q4 earnings. EPS was reported at -0.10, versus the expected -0.09, missing expectations. The chart below visualizes how ONCY has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime